Monopar Therapeutics heads into its August earnings window with a stock that has more than doubled off its lows, shorts quietly trimming exposure, and the Street nudging targets higher — yet the borrow market remains tight enough to keep this a charged setup.
The most striking feature of the past month is the rally itself. MNPR has gained 68% in a month and 14% in the past week alone, closing Tuesday at $113.57. That kind of move in a clinical-stage micro-cap biotech — pre-revenue, burning cash, highly concentrated in a single pipeline bet on Wilson Disease candidate ALXN1840 — reflects a sharp sentiment shift rather than fundamental re-rating. The backdrop is FDA optionality: positive regulatory guidance has converted skeptics into momentum chasers.
Short sellers are acknowledging the pain, but they have not capitulated. Short interest has slipped from a one-month peak near 1.66 million shares in mid-June to roughly 1.48 million shares now, a decline of about 8.5% over the period. At 22.2% of the free float, this is still meaningfully elevated — well into territory where any catalyst-driven buying can create a feedback loop. The ORTEX short score sits at 79.8, placing MNPR in the 3rd percentile of the short-score universe, meaning this ranks as one of the more pressured borrowing environments in the database. Availability tells a similar story: currently at 30%, with only about one share available for every three already lent out. That's tight — though notably looser than the 52-week trough, when availability dropped to just 2.5% in mid-June as utilization hit 100% and the lending pool was entirely drained. The borrow has since loosened materially, with availability climbing from those extreme lows over the past five weeks. Cost to borrow has ticked up 11% on the week to 2.67% annually — unremarkable in absolute terms, and well below the levels that would typically flag a squeeze in progress.
On the Street, the direction of travel is unambiguously bullish, even if the unanimous buy consensus carries the usual caveats of thin small-cap coverage. HC Wainwright raised its target this week to $125 from $105, the most recent action and the closest to current price. BTIG lifted to $117 from $104 at the end of June. The consensus mean target of $116.85 sits barely above the current price of $113.57, which matters: after a 68% month, the implied upside from analyst models has essentially been consumed. The bull case rests on ALXN1840's path through FDA review and Monopar's broader radiopharmaceutical pipeline; the bear case centres on the company's pre-revenue status, net losses, dependence on external financing, and the structural challenge of building market share in a rare-disease niche. The price-to-book multiple has expanded sharply — up roughly 3.2 points over the past 30 days to 7.9x — reflecting the stock's re-rating rather than any improvement in underlying book value.
The institutional register offers an interesting footnote. AstraZeneca holds 7.8% of shares — a meaningful strategic stake that anchors the clinical credibility story. Janus Henderson tops the holder list at 19.7%. Among recent movers, Deerfield Management added 153,000 shares in Q1, and Polar Capital added nearly 121,000. Adage Capital trimmed 290,000 shares in the same period — the most notable reduction in the register. On the insider side, the June 30 activity was routine: award grants to the CEO, COO, and CFO, offset by small same-day sells to cover tax obligations at $92.59 — well below the current price, suggesting those sales were mechanical rather than discretionary.
The August 14 earnings report is the next binary moment. The recent history on those events has been modest in amplitude: four prints produced day-one moves of between -3.5% and +5%, nothing dramatic for a stock capable of moving 14% in a week on sentiment alone. What matters more is pipeline news flow — any update on ALXN1840's regulatory timeline or trial design ahead of that print could dwarf any quarterly financial data in a company with no revenue to report. The key tension to watch is whether short sellers, who have been steadily trimming but remain at 22% of float, continue their retreat in the face of rising prices, or whether the stock's approach to analyst targets — with HC Wainwright's new $125 ceiling now only 10% away — begins to dampen buying momentum.
See the live data behind this article on ORTEX.
Open MNPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
